Prevention of myocardial fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats

Clinical Science

Volumn 118, Issue 3, 2010, Pages 211-220

  Castoldi, Giovanna ^a,b   di Gioia, Cira R T ^c   Bombardi, Camila ^a,b   Perego, Carla ^d   Perego, Lucia ^a,b   Mancini, Massimiliano ^c   Leopizzi, Martini ^c   Gorradi, Barbara ^a,b   Perlini, Stefano ^e   Zerbini, Gianpaolo ^f   Stella, Andrea ^a,b  

^a Clinica Nefrologica   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY OF PAVIA   (Italy)

^f SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Angiotensin converting enzyme inhibitor (ACEI); Diabetic cardiomyopathy; Echocardiography; Fibrosis; N acetyl seryl aspartyl lysyl proline (Ac SDKP); Smad; Transforming growth factor 1 (TGF 1)

Indexed keywords

GLUCOSE; INSULIN; OSMOTIC AGENT; RAMIPRIL; SERASPENIDE; SMAD2 PROTEIN; SMAD3 PROTEIN; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG ACTIVITY; DRUG EFFICACY; ELECTROCARDIOGRAPHY; GLUCOSE BLOOD LEVEL; HEART MUSCLE FIBROSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SPRAGUE DAWLEY RAT; STREPTOZOCIN DIABETES; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CARDIOMYOPATHIES; DIABETES COMPLICATIONS; DIABETES MELLITUS, EXPERIMENTAL; FIBROSIS; HEART VENTRICLES; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MYOCARDIUM; OLIGOPEPTIDES; RAMIPRIL; RATS; RATS, SPRAGUE-DAWLEY; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 70549095863     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20090234     Document Type: Article

References (34)

1. Fox, C. S., Coady, S., Sorlie, P. D., Sorlie, P. D., D'Agostino, R. B., Pencina, J. M., Ramachandran, S. V., Meigs, J. B., Levy, D. and Savage, P. J. (2007) Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 115, 1544-1550
2. Bell, D. S. (1995) Diabetic cardiomyopathy. A unique entity or a complication of coronary artery disease? Diabetes Care 18, 708-714
3. Fang, Z. Y., Prins, J. B. and Marwick, T. H. (2004) Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr. Rev. 25, 543-567
4. Rubler, S., Dlugash, J., Yuceoglu, Y. Z., Kumral, T., Branwood, A. W. and Grishman, A. (1972) New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am. J. Cardiol. 30, 595-602
5. Poornima, I. G., Parikh, P. and Shannon, R. P. (2006) Diabetic Cardiomyopathy: the search for a unifying hypothesis. Circ. Res. 98, 596-605
6. Dhalla, N. S., Liu, X., Panagia, V. and Takeda, N. (1998) Subcellular remodeling and heart dysfunction in chronic diabetes. Cardiovasc. Res. 40, 239-247
7. Ferrari, P. (2007) Prescribing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease. Nephrology 12, 81-89
8. Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., Laurent, S. et al. (2007) 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J. Hypertens. 25, 1751-1762
9. Turnbull, F., Neal, B., Pfeffer, M., Kostis, J., Algert, C., Woodward, M., Chalmers, J., Zanchetti, A. and MacMahon, S. (2007) Blood pressure-dependent and independent effects of agents that inhibit the renin - angiotensin system. J. Hypertens. 25, 951-958
10. Azizi, M., Rousseau, A., Ezan, E., Guyene, T. T., Michelet, S., Grognet, J. M., Lenfant, M., Corvol, P. and Menard, J. (1996) Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J. Clin. Invest. 97, 839-844
11. Rasoul, S., Carretero, O. A., Peng, H., Cavasin, M. A., Zhuo, J., Sanchez-Mendoza, A., Brigstock, D. R. and Rhaleb, N. E. (2004) Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension. J. Hypertens. 22, 593-603
12. Peng, H., Carretero, O. A., Raij, L., Yang, F., Kapke, A. and Rhaleb, N. E. (2001) Antifibrotic effects of N-acetyl-seryl-aspartyl-lysyl-proline on the heart and kidney in aldosterone-salt hypertensive rats. Hypertension 37, 794-800
13. Peng, H., Carretero, O. A., Liao, T. D., Peterson, E. L. and Rhaleb, N. E. (2007) Role of N-acetyl-seryl-aspartyl-lysyl-proline in the antifibrotic and anti-inflammatory effects of the angiotensin-converting enzyme inhibitor captopril in hypertension. Hypertension 49, 695-703
14. Peng, H., Carretero, O. A., Vuljaj, N., Liao, T. D., Motivala, A., Peterson, E. L. and Rhaleb, N. E. (2005) Angiotensin converting enzyme inhibitors: a new mechanism of action. Circulation 112, 2436-2445
15. Asbun, J. and Villarreal, F. J. (2006) The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J. Am. Coll. Cardiol. 47, 693-700
16. Chung, E. S., Perlini, S., Aurigemma, G. P., Fenton, R. A., Dobson, Jr, J. G. and Meyer, T. E. (1998) Effects of chronic adenosine uptake blockade on adrenergic responsiveness and left ventricular chamber function in pressure overload hypertrophy in the rat. J. Hypertens. 16, 1813-1822
17. Perlini, S., Ferrero, I., Palladini, G., Tozzi, R., Gatti, C., Vezzoli, M., Cesana, F., Janetti, M. B., Clari, F., Busca, G. et al. (2006) Survival benefits of different antiadrenergic interventions in pressure overload left ventricular hypertrophy/failure. Hypertension 48, 93-97
18. Infanger, M., Grosse, J., Westphal, K., Leder, A., Ulbrich, C., Paul, M. and Grimm, D. (2008) Vascular endothelial growth factor induces extracellular matrix proteins and osteopontin in the umbilical artery. Ann. Vasc. Surg. 22, 273-284
19. Osicka, T. M., Yu, Y., Panagiotopoulos, S., Clavant, S. P., Kiriazis, Z., Pike, R. N., Pratt, L. M., Russo, L. M., Kemp, B. E., Comper, W. D. and Jerums, G. (2000) Prevention of albuminuria by aminoguanidine or ramipril in streptozotocin-induced diabetic rats is associated with the normalization of glomerular protein kinase C. Diabetes 49, 87-93
20. Walther, T., Schuitheiss, H. P. and Tschöpe, C. (2001) Impaired angiotensin II regulation of renal C-type natriuretic peptide mRNA expression in experimental diabetes mellitus. Cardiovasc. Res. 51, 562-566
21. Rhaleb, N. E., Peng, H., Yang, X. P., Liu, Y. H., Mehta, D., Ezan, E. and Carretero, O. A. (2001) Long-term effect of N-acetyl-seryl-aspartyl-lysyl-proline on left ventricular collagen deposition in rats with 2-kidney, 1-clip hypertension. Circulation 103, 3136-3141
22. Yang, F., Yang, X. P., Liu, Y. H., Xu, J., Cingolani, O., Rhaleb, N. E. and Carretero, O. A. (2004) Ac-SDKP reverses inflammation and fibrosis in rats with heart failure after myocardial infarction. Hypertension 43, 229-236
23. Cavasin, M. A., Liao, T. D., Yang, X. P., Yang, J. J. and Carretero, O. A. (2007) Decreased endogenous levels of Ac-SDKP promote organ fibrosis. Hypertension 50, 1-7
24. Reuter, H., Adam, C., Grönke, S., Zobel, C., Frank, K. F., Müller-Ehmsen, J., Brabender, J. and Schwinger, R. H. G. (2006) The increased angiotensin II (type 1) receptor density in myocardium of type 2 diabetic patients is prevented by blockade of the renin-angiotensin system. Diabetologia 49, 3067-3074
25. Sechi, L. A., Griffin, C. A. and Schambelan, M. (1994) The cardiac renin-angiotensin system in STZ-induced diabetes. Diabetes 43, 1180-1184
26. Ruiz-Ortega, M., Rodríguez-Vita, J., Sanchez-Lopez, E., Carvajal, G. and Egido, J. (2007) TGF-β signaling in vascular fibrosis. Cardiovasc. Res. 74, 196-206
27. Kanasaki, K., Koya, D., Sugimoto, T., Isono, M., Kashiwagi, A. and Haneda, M. (2003) N-acetyl-seryl-aspartyl-lysyl-proline inhibits TGF-β mediated plasminogen activator inhibitor-1 expression via inhibition of smad pathway in human mesangial cells. J. Am. Soc. Nephrol. 14, 863-872
28. Pokharel, S., Rasoul, S., Roks, A. J. M., van Leeuwen, R. E. W., van Luyn, M. J. A., Deelman, L. E., Smits, J. F., Carretero, O., van Gilst, W. H. and Pinto, Y. M. (2002) N-acetyl-Ser-Asp-Lys-Pro inhibits phosphorylation of Smad2 in cardiac fibroblasts. Hypertension 40, 155-161
29. Liu, X., Suzuki, H., Sethi, R., Tappia, P. S., Takeda, N. and Dhalla, N. S. (2006) Blockade of the renin-angiotensin system attenuates sarcolemma and sarcoplasmic reticulum remodeling in chronic diabetes. Ann. N. Y. Acad. Sci. 1084, 141-154
30. Fiordaliso, F., Cuccovillo, I., Bianchi, R., Bai, A., Doni, M., Salio, M., De Angelis, N., Ghezzi, P., Latini, R. and Masson, S. (2006) Cardiovascular oxidative stress is reduced by an ACE inhibitor in a rat model of streptozotocin-induced diabetes. Life Sci. 79, 121-129
31. Nathan, D. M., Cleary, P. A., Backlund, J. Y. C., Genuth, S. M., Lachin, J. M., Orchard, T. J., Raskin, P. and Zinman, B. (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 353, 2643-2653
32. Coats, A. J. and Anker, S. (2000) Insulin resistance in chronic heart failure. J Cardiovasc. Pharmacol. 35, S9-14
33. Samuelsson, A. M., Bollano, E., Mobini, R., Larsson, B. M., Omerovic, E., Fu, M., Waagstein, F. and Holmäng, A. (2006) Hyperinsulinemia: effect on cardiac mass/function, angiotensin II receptor expression, and insulin signaling pathways. Am. J. Physiol. Heart Circ. Physiol. 291, H787-H796
34. van Heerebeek, L., Hamdani, N., Handoko, M. L., Falcao-Pires, I., Musters, R. J., Kupreishvili, K., Ijsselmuiden, A. J., Schalkwijk, C. G., Bronzwaer, J. G., Diamant, M. et al. (2008) Diastolic stiffness of the failing diabetic heart. Importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 117, 43-51